USANA Health Sciences Inc.

What does USANA Health Sciences own?

USANA sells nutritional supplements, personal care, and wellness products under a single master brand, with product lines including CellSentials, Celavive, and Proglucamune rather than separate brands.

Is USANA Health Sciences publicly traded?

Yes. USANA trades on the New York Stock Exchange under the ticker USNA.

Who founded USANA Health Sciences?

Microbiologist and immunologist Myron Wentz founded the company in 1992 after building his scientific reputation through viral diagnostics at Gull Laboratories. He remains chairman.

Where is USANA Health Sciences headquartered?

The company is headquartered in Salt Lake City, Utah, where it also operates its main manufacturing facility. A second plant operates in China.

How many brands does USANA Health Sciences own?

It operates under the single USANA master brand, with named product lines rather than a multi-brand portfolio.

Who owns USANA Health Sciences?

USANA is publicly owned by shareholders through its NYSE listing. Founder Myron Wentz remains chairman and a significant insider, but control rests with public stockholders.

What is USANA Health Sciences' revenue?

The company reported 925.3 million dollars in net sales for fiscal 2025, with net income of 31.4 million dollars. Asia Pacific is its largest regional market.

Myron Wentz founded USANA in 1992 after establishing a scientific reputation through his earlier company, Gull Laboratories, which developed viral diagnostic assays. Wentz, a microbiologist and immunologist, launched USANA to apply cellular nutrition science to consumer supplements, and he continues to serve as chairman.

The company adopted a direct sales structure from the start, recruiting independent Associates to sell products rather than using retail distribution. It went public on the NASDAQ in 1996 and later moved its listing to the NYSE, giving it access to capital while retaining founder control.

International expansion drove growth through the 2000s and 2010s, with Asia Pacific becoming its dominant market as direct selling flourished in China and Southeast Asia. It opened manufacturing in China to serve that region, complementing its Utah production base.

Recent years have been harder. Net sales fell from roughly 1 billion dollars in 2022 to 925.3 million dollars in fiscal 2025, with soft distributor activity and currency pressure weighing on results. The company has responded with product reformulation, market expansion, and cost discipline under CEO Jim Brown.

USANA reports corporate responsibility efforts including charitable giving through the USANA Foundation, which funds nutrition programs for children in need, and sustainability initiatives across its manufacturing operations.

Its ethical posture is tied to the direct sales model, which carries inherent scrutiny around distributor earnings and recruitment. USANA publishes income disclosures and emphasizes product quality and science-backed formulations as its differentiation within a category that faces persistent regulatory attention.

USANA has faced criticism common to multi-level marketers, including questions about distributor income distribution and the gap between headline earnings claims and median Associate results. It publishes income disclosure statements but operates in a business model that attracts regulatory attention.

The FTC and international regulators periodically examine direct selling practices, and USANA has adjusted compensation structures over the years in response. Its NYSE listing means these risks are disclosed publicly, a transparency advantage over private direct sellers, but the model itself remains a structural point of scrutiny.